ANKS1A

Across TCGA pan-cancer cohorts, ANKS1A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ANKS1A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ANKS1A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ANKS1A is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where ANKS1A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKS1A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−0.306	<.001	11	view →
LSCC	Female	II,III,IV	−0.411	<.001	9	view →
LUAD	Female	III,IV	−0.383	<.001	9	view →
COAD	Female	All	−0.155	<.001	7	view →
HNSC	Female	All	+0.273	.025	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ANKS1A–CCRCC

Open the CCRCC breakdown →